[English] 日本語
Yorodumi
- EMDB-60686: Cryo-EM structure for the GPRC5D complexed with Talquetamab Fab -

+
Open data


ID or keywords:

Loading...

-
Basic information

Entry
Database: EMDB / ID: EMD-60686
TitleCryo-EM structure for the GPRC5D complexed with Talquetamab Fab
Map data
Sample
  • Complex: GPCR antibody complex
    • Complex: antibody
      • Protein or peptide: Talquetamab Fab (anti-GPRC5D) Heavy chain
      • Protein or peptide: Talquetamab Fab (anti-GPRC5D) Light chain
    • Complex: GPCR
      • Protein or peptide: G-protein coupled receptor family C group 5 member D
  • Ligand: CHOLESTEROL
KeywordsTalquetamab / class C GPCR / multiple myeloma / bispecific antibody / MEMBRANE PROTEIN-IMMUNE SYSTEM complex
Function / homology
Function and homology information


protein kinase activator activity / G protein-coupled receptor activity / receptor complex / intracellular membrane-bounded organelle / extracellular exosome / plasma membrane
Similarity search - Function
: / GPCR family 3, C-terminal / 7 transmembrane sweet-taste receptor of 3 GCPR
Similarity search - Domain/homology
G-protein coupled receptor family C group 5 member D
Similarity search - Component
Biological speciesMus musculus (house mouse) / Homo sapiens (human)
Methodsingle particle reconstruction / cryo EM / Resolution: 2.65 Å
AuthorsJeong J / Shin J / Park J / Cho Y
Funding support Korea, Republic Of, 1 items
OrganizationGrant numberCountry
National Research Foundation (NRF, Korea)2021R1A2C301335711 Korea, Republic Of
CitationJournal: J Mol Biol / Year: 2024
Title: Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma.
Authors: Jihong Jeong / Junhyeon Park / Geun Young Mo / Jinwoo Shin / Yunje Cho /
Abstract: Multiple myeloma (MM) is a complex hematological malignancy characterized by abnormal antibody production from plasma cells. Despite advances in the treatment, many patients experience disease ...Multiple myeloma (MM) is a complex hematological malignancy characterized by abnormal antibody production from plasma cells. Despite advances in the treatment, many patients experience disease relapse or become refractory to treatment. G-protein-coupled receptor class C group 5 member D (GPRC5D), an orphan GPCR predominantly expressed in MM cells, is emerging as a promising target for MM immunotherapy. Talquetamab, a Food and Drug Administration-approved T-cell-directing bispecific antibody developed for treatment of MM, targets GPRC5D. Here, we elucidate the structure of GPRC5D complexed with the Fab fragment of talquetamab, using cryo-electron microscopy, providing the basis for recognition of GPRC5D by the bispecific antibody. GPRC5D forms a symmetric homodimer with the interface between transmembrane helix (TM) 4 of one protomer and TM4/5 of the other protomer. A single talquetamab Fab interacts with the GPRC5D dimer with its orientation toward the dimer interface. All six complementarity-determining regions of talquetamab engage with extracellular loops and TM3/5/7. In particular, the side-chain of an arginine residue from the antibody penetrates into a shallow pocket on the extracellular surface of GPRC5D. The structure offers insights for optimizing antibody design against GPRC5D for relapsed or refractory MM therapy.
History
DepositionJul 2, 2024-
Header (metadata) releaseSep 11, 2024-
Map releaseSep 11, 2024-
UpdateSep 11, 2024-
Current statusSep 11, 2024Processing site: PDBj / Status: Released

-
Structure visualization

Supplemental images

Downloads & links

-
Map

FileDownload / File: emd_60686.map.gz / Format: CCP4 / Size: 193.2 MB / Type: IMAGE STORED AS FLOATING POINT NUMBER (4 BYTES)
Projections & slices

Image control

Size
Brightness
Contrast
Others
AxesZ (Sec.)Y (Row.)X (Col.)
0.83 Å/pix.
x 370 pix.
= 305.805 Å
0.83 Å/pix.
x 370 pix.
= 305.805 Å
0.83 Å/pix.
x 370 pix.
= 305.805 Å

Surface

Projections

Slices (1/3)

Slices (1/2)

Slices (2/3)

Images are generated by Spider.

Voxel sizeX=Y=Z: 0.8265 Å
Density
Contour LevelBy AUTHOR: 0.3
Minimum - Maximum-0.74638516 - 1.2379642
Average (Standard dev.)-0.00020127432 (±0.030147834)
SymmetrySpace group: 1
Details

EMDB XML:

Map geometry
Axis orderXYZ
Origin000
Dimensions370370370
Spacing370370370
CellA=B=C: 305.805 Å
α=β=γ: 90.0 °

-
Supplemental data

-
Half map: #1

Fileemd_60686_half_map_1.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

-
Half map: #2

Fileemd_60686_half_map_2.map
Projections & Slices
AxesZYX

Projections

Slices (1/2)
Density Histograms

-
Sample components

-
Entire : GPCR antibody complex

EntireName: GPCR antibody complex
Components
  • Complex: GPCR antibody complex
    • Complex: antibody
      • Protein or peptide: Talquetamab Fab (anti-GPRC5D) Heavy chain
      • Protein or peptide: Talquetamab Fab (anti-GPRC5D) Light chain
    • Complex: GPCR
      • Protein or peptide: G-protein coupled receptor family C group 5 member D
  • Ligand: CHOLESTEROL

-
Supramolecule #1: GPCR antibody complex

SupramoleculeName: GPCR antibody complex / type: complex / ID: 1 / Parent: 0 / Macromolecule list: #1-#3

-
Supramolecule #2: antibody

SupramoleculeName: antibody / type: complex / ID: 2 / Parent: 1 / Macromolecule list: #1-#2
Source (natural)Organism: Mus musculus (house mouse)

-
Supramolecule #3: GPCR

SupramoleculeName: GPCR / type: complex / ID: 3 / Parent: 1 / Macromolecule list: #3
Source (natural)Organism: Homo sapiens (human)

-
Macromolecule #1: Talquetamab Fab (anti-GPRC5D) Heavy chain

MacromoleculeName: Talquetamab Fab (anti-GPRC5D) Heavy chain / type: protein_or_peptide / ID: 1 / Number of copies: 1 / Enantiomer: LEVO
Source (natural)Organism: Mus musculus (house mouse)
Molecular weightTheoretical: 25.137211 KDa
Recombinant expressionOrganism: Trichoplusia ni (cabbage looper)
SequenceString: QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL INPYNSDTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSD DTAVYYCARV ALRVALDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW N SGALTSGV ...String:
QVQLVQSGAE VKKPGASVKV SCKASGYSFT GYTMNWVRQA PGQGLEWMGL INPYNSDTNY AQKLQGRVTM TTDTSTSTAY MELRSLRSD DTAVYYCARV ALRVALDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW N SGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGLVPRGSH HHHHH

-
Macromolecule #2: Talquetamab Fab (anti-GPRC5D) Light chain

MacromoleculeName: Talquetamab Fab (anti-GPRC5D) Light chain / type: protein_or_peptide / ID: 2 / Number of copies: 1 / Enantiomer: LEVO
Source (natural)Organism: Mus musculus (house mouse)
Molecular weightTheoretical: 23.666236 KDa
Recombinant expressionOrganism: Trichoplusia ni (cabbage looper)
SequenceString: DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS ASYRYSGVPS RFSGSGSGTE FTLTISNLQP EDFATYYCQ QYNRYPYTFG QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS Q ESVTEQDS ...String:
DIQMTQSPSS LSASVGDRVT ITCKASQNVA THVGWYQQKP GKAPKRLIYS ASYRYSGVPS RFSGSGSGTE FTLTISNLQP EDFATYYCQ QYNRYPYTFG QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS Q ESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH QGLSSPVTKS FNRGEC

-
Macromolecule #3: G-protein coupled receptor family C group 5 member D

MacromoleculeName: G-protein coupled receptor family C group 5 member D / type: protein_or_peptide / ID: 3 / Number of copies: 2 / Enantiomer: LEVO
Source (natural)Organism: Homo sapiens (human)
Molecular weightTheoretical: 39.540027 KDa
Recombinant expressionOrganism: Homo sapiens (human)
SequenceString: MVDMYKDCIE STGDYFLLCD AEGPWGIILE SLAILGIVVT ILLLLAFLFL MRKIQDCSQW NVLPTQLLFL LSVLGLFGLA FAFIIELNQ QTAPVRYFLF GVLFALCFSC LLAHASNLVK LVRGCVSFSW TTILCIAIGC SLLQIIIATE YVTLIMTRGM M FVNMTPCQ ...String:
MVDMYKDCIE STGDYFLLCD AEGPWGIILE SLAILGIVVT ILLLLAFLFL MRKIQDCSQW NVLPTQLLFL LSVLGLFGLA FAFIIELNQ QTAPVRYFLF GVLFALCFSC LLAHASNLVK LVRGCVSFSW TTILCIAIGC SLLQIIIATE YVTLIMTRGM M FVNMTPCQ LNVDFVVLLV YVLFLMALTF FVSKATFCGP CENWKQHGRL IFITVLFSII IWVVWISMLL RGNPQFQRQP QW DDPVVCI ALVTNAWVFL LLYIVPELCI LYRSCRQECP LQGNACPVTA YQHSFQVENQ ELSRARDSDG AEEDSGSGSG RGR GGSENL YFQGGSGSGG DYKDDDDKDY KDDDDK

UniProtKB: G-protein coupled receptor family C group 5 member D

-
Macromolecule #4: CHOLESTEROL

MacromoleculeName: CHOLESTEROL / type: ligand / ID: 4 / Number of copies: 6 / Formula: CLR
Molecular weightTheoretical: 386.654 Da
Chemical component information

ChemComp-CLR:
CHOLESTEROL

-
Experimental details

-
Structure determination

Methodcryo EM
Processingsingle particle reconstruction
Aggregation stateparticle

-
Sample preparation

Concentration8.3 mg/mL
BufferpH: 7.5
VitrificationCryogen name: ETHANE

-
Electron microscopy

MicroscopeFEI TITAN KRIOS
Image recordingFilm or detector model: GATAN K3 BIOQUANTUM (6k x 4k) / Average electron dose: 60.0 e/Å2
Electron beamAcceleration voltage: 300 kV / Electron source: FIELD EMISSION GUN
Electron opticsIllumination mode: OTHER / Imaging mode: OTHER / Cs: 2.73 mm / Nominal defocus max: 1.8 µm / Nominal defocus min: 0.8 µm
Experimental equipment
Model: Titan Krios / Image courtesy: FEI Company

+
Image processing

Startup modelType of model: INSILICO MODEL
Final reconstructionResolution.type: BY AUTHOR / Resolution: 2.65 Å / Resolution method: FSC 0.143 CUT-OFF / Number images used: 628867
Initial angle assignmentType: OTHER
Final angle assignmentType: OTHER
FSC plot (resolution estimation)

+
About Yorodumi

-
News

-
Feb 9, 2022. New format data for meta-information of EMDB entries

New format data for meta-information of EMDB entries

  • Version 3 of the EMDB header file is now the official format.
  • The previous official version 1.9 will be removed from the archive.

Related info.:EMDB header

External links:wwPDB to switch to version 3 of the EMDB data model

-
Aug 12, 2020. Covid-19 info

Covid-19 info

URL: https://pdbj.org/emnavi/covid19.php

New page: Covid-19 featured information page in EM Navigator.

Related info.:Covid-19 info / Mar 5, 2020. Novel coronavirus structure data

+
Mar 5, 2020. Novel coronavirus structure data

Novel coronavirus structure data

Related info.:Yorodumi Speices / Aug 12, 2020. Covid-19 info

External links:COVID-19 featured content - PDBj / Molecule of the Month (242):Coronavirus Proteases

+
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)

EMDB accession codes are about to change! (news from PDBe EMDB page)

  • The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
  • The EM Navigator/Yorodumi systems omit the EMD- prefix.

Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator

External links:EMDB Accession Codes are Changing Soon! / Contact to PDBj

+
Jul 12, 2017. Major update of PDB

Major update of PDB

  • wwPDB released updated PDB data conforming to the new PDBx/mmCIF dictionary.
  • This is a major update changing the version number from 4 to 5, and with Remediation, in which all the entries are updated.
  • In this update, many items about electron microscopy experimental information are reorganized (e.g. em_software).
  • Now, EM Navigator and Yorodumi are based on the updated data.

External links:wwPDB Remediation / Enriched Model Files Conforming to OneDep Data Standards Now Available in the PDB FTP Archive

-
Yorodumi

Thousand views of thousand structures

  • Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
  • This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
  • The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.

Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi

Read more